Last reviewed · How we verify

NCT03836638

The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment

Status unknown NA Last updated 11 February 2019
What this trial tests

NA trial testing 30 Units of botulinum toxin in Aging in 45 participants. Status unknown.

Timeline
1 May 2019
Primary endpoint
1 December 2020
1 December 2020

Quick facts

Lead sponsorSt Joseph University, Beirut, Lebanon
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment45
Start date1 May 2019
Primary completion1 December 2020
Estimated completion1 December 2020
Sites1 location across Lebanon

Drugs / interventions tested

Conditions studied

Sponsor

St Joseph University, Beirut, Lebanon

Who can join

25 and older, any sex, with Aging or Botulinum Toxin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Botulinum toxin is approved by the FDA for the treatment of facial wrinkles. Patients are usually older than 45 years and their main demand is to treat pre-existing facial wrinkles. However with the increasing popularity of this technique, younger patients, aged 25 to 35 years, are now seeking botulinum toxin injection as a preventive measure for rhytides. The usual dose used for the treatment of facial rhytides in a female patient older than 45 years is 50 units. No consensus exists concerning the dose of botulinum toxin that should be used in younger patients. Hypothesis: lower dose of botulinum toxin is sufficient to give good and long lasting results in young patients. The objective of this randomized open-label study is to evaluate the effect of lower doses of Botulinum toxin on the facial rythides in young patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aging

Currently open trials in the same condition.

Other St Joseph University, Beirut, Lebanon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03836638.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing